Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.

被引：0

作者：

Cruz-Correa, Marcia

Xu, Rui-Hua

Moehler, Markus H.

Oh, Do-Youn

Kato, Ken

Spigel, David R.

Arkenau, Hendrik-Tobias

Tabernero, Josep

Zimina, Anastasia V.

Bai, Yuxian

Shi, Jianhua

Lee, Keun-Wook

Hirano, Hidekazu

Wyrwicz, Lucjan S.

Pazo Cid, Roberto

Xu, Hui

Sheng, Tao

Barnes, Gisoo

机构：

[1] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA

[2] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China

[3] Johannes Gutenberg Univ Clin, Dept Internal Med, Mainz, Germany

[4] Seoul Natl Univ Hosp, Dept Internal Med, Div Med Oncol, Seoul, South Korea

[5] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea

[6] Natl Canc Ctr, Tokyo, Japan

[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[8] Sarah Cannon Res, London, England

[9] Vall DHebron Univ Hosp & Inst Oncol VHIO, Barcelona, Spain

[10] BHI Omsk Reg Clin Oncol Dispensary, Omsk, Russia

[11] Harbin Med Univ Canc Hosp, Dept Gastrointestinal Oncol, Harbin, Peoples R China

[12] Linyi Canc Hosp, Dept Med Oncol, Linyi, Peoples R China

[13] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea

[14] Natl Canc Ctr Hosp, Dept Gastrointestinal Med Oncol, Chuo City, Japan

[15] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[16] Hosp Univ Miguel Servet, Zaragoza, Spain

[17] BeiGene Beijing Co Ltd, Beijing, Peoples R China

[18] BeiGene USA Inc, San Mateo, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

261-566-148; 613-135-2370-7650-2700; 130-274-2403; 613-302-309; 613-302-312-303; 17; 9; 3; 2; 2424; 1704;

D O I：

10.1200/JCO.2024.42.3_suppl.290

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：290 / 290

页数：1

共 50 条

[21] Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Lowery, M.
Wyrwicz, L.
Oh, D-Y.
Shiu, K. K.
Weber, P. Yanez
Bai, Y.
Lee, J.
Rivera, F.
Alves, G.
Garrido, M.
Fernandez, M. Gonzalez
Li, J.
Cil, T.
Cruz, F.
Qin, S.
Yin, L.
Valderrama, A.
Bordia, S.
Rha, S. Y.
ANNALS OF ONCOLOGY, 2023, 34 : S854 - S855
[22] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
Janjigian, Yelena Y.
Shitara, Kohei
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Maya, Ricardo Elias Bruges
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Amaya-Chanaga, Carlos
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 291 - 291
[23] Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649
Shitara, Kohei
Janjigian, Yelena Y.
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Silva, Arinilda
Bragagnoli, Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Soleymani, Samira
Lei, Ming
Kondo, Kaoru
Li, Mingshun
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[24] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
Qiu, Miao-Zhen
Oh, Do-Youn
Kato, Ken
Arkenau, Tobias
Tabernero, Josep
Correa, Marcia Cruz
Zimina, Anastasia, V
Bai, Yuxian
Shi, Jianhua
Lee, Keun-Wook
Wang, Jufeng
Poddubskaya, Elena
Pan, Hongming
Rha, Sun Young
Zhang, Ruixing
Hirano, Hidekazu
Spigel, David
Yamaguchi, Kensei
Chao, Yee
Wyrwicz, Lucjan
Disel, Umut
Cid, Roberto Pazo
Fornaro, Lorenzo
Evesque, Ludovic
Wang, Hongwei
Xu, Yaling
Li, Jiang
Sheng, Tao
Yang, Silu
Li, Liyun
Moehler, Markus
Xu, Rui-Hua
BMJ-BRITISH MEDICAL JOURNAL, 2024, 385
[25] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
Moehler, Markus H.
Shitara, Kohei
Garrido, Marcelo
Salman, Pamela
Shen, Lin
Wyrwicz, Lucjan
Yamaguchi, Kensei
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Schenker, Michael
Yanez, Patricio Eduardo
Tehfe, Mustapha
Li, Mingshun
Cullen, Dana
Memaj, Arteid
Lei, Ming
Xiao, Hong
Janjigian, Yelena Y.
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[26] First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Ruihua
Guo, Weijian
Qin, Shukui
Yang, Nong
Lu, Jianwei
Shitara, Kohei
Lei, Ming
Li, Mingshun
Bao, Nicole
Chen, Tian
Liu, Tianshu
CANCER RESEARCH, 2021, 81 (13)
[27] Health-related quality of life (HRQoL) with pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355
Cescon, D. W.
Schmid, P.
Rugo, H. S.
Im, S-A.
Yusof, M. Md
Gallardo, C. E.
Lipatov, O.
Barrios, C. H.
Perez Garcia, J. M.
Iwata, H.
Masuda, N.
Torregroza Otero, M. A.
Gokmen, E.
Loi, S.
Haiderali, A.
Zhou, X.
Guo, Z.
Nguyen, A. Martin
Cortes, J.
ANNALS OF ONCOLOGY, 2022, 33 : S197 - S198
[28] Randomized, global, phase 3 study of tislelizumab (TIS) plus chemotherapy (chemo) versus placebo (PBO) plus chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.
Raymond, Eric
Hubner, Richard
Gotovkin, Evgeny
Wyrwicz, Lucjan
Van Cutsem, Eric
Jimenez-Fonseca, Paula
Pazo-Cid, Roberto
Xu, Jianming
Kato, Ken
Tao, Aiyang
Wang, Lei
Peng, Yanyan
Li, Liyun
Yoon, Harry H.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 340 - 340
[29] Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
Cruz-Correa, M.
Oh, D-Y.
Kato, K.
Tabernero, J.
Bai, Y.
Shi, J.
Lee, K-W.
Hirano, H.
Spigel, D. R.
Wyrwicz, L. S.
Pazo Cid, R. A.
Cubillo Gracian, A.
Li, L.
Xu, Y.
Sheng, T.
Yang, S.
Xu, R-H.
Moehler, M.
ANNALS OF ONCOLOGY, 2024, 35 : S893 - S894
[30] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.
Janjigian, Yelena Y.
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Cleary, James M.
Elimova, Elena
Bruges, Ricardo Elias
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
McCraith, Stephen
Hu, Nan
Zhang, Jennifer
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 398 - 398

← 1 2 3 4 5 →